• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by aTyr Pharma Inc.

    10/15/24 5:01:55 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATYR alert in real time by email
    SC 13G 1 p24-2974sc13g.htm ATYR PHARMA, INC.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No.  )*
     

    aTyr Pharma, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    002120202

    (CUSIP Number)
     

    October 14, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     

    CUSIP No. 00212020213GPage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,039,846

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,039,846

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,039,846

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 00212020213GPage 3 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,039,846

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,039,846

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,039,846

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 00212020213GPage 4 of 7 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,039,846

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,039,846

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,039,846

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.2%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 00212020213GPage 5 of 7 Pages

     

     

    Item 1(a). Name of Issuer.

     

      aTyr Pharma, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      10240 Sorrento Valley, Suite 300, San Diego, CA 92121.

     

    Item 2(a). Name of Person Filing.
     

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Shares”), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by Point72 Associates; and (iii) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.

     

     

    Each of Cubist Systematic Strategies, LLC and Point72 Asia (Singapore) Pte. Ltd. are advisors under common control with Point72 Asset Management, and each acts as a sub-advisor with respect to a portion of the Shares reported herein.

     

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.001 per share.

     

    Item 2(e). CUSIP Number.
      002120202

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on October 14, 2024.

     

     

    CUSIP No. 00212020213GPage 6 of 7 Pages

     

     

    Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

      The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person is based on 80,796,198 Shares outstanding which is the sum of: (i) 75,796,198 Shares outstanding as of August 9, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 13, 2024; and (ii) 5,000,000 Shares purchased by Point72 Associates in the at the market offering by the Issuer.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 00212020213GPage 7 of 7 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: October 15, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       

     

      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       

     

      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       

     

     

    Get the next $ATYR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATYR

    DatePrice TargetRatingAnalyst
    9/16/2025$1.50Outperform → Sector Perform
    RBC Capital Mkts
    9/15/2025$1.00Overweight → Equal Weight
    Wells Fargo
    9/15/2025Buy → Neutral
    H.C. Wainwright
    9/15/2025$1.00Outperform → Market Perform
    Leerink Partners
    9/15/2025Overweight → Neutral
    Cantor Fitzgerald
    2/18/2025$16.00Outperform
    Leerink Partners
    1/6/2025Overweight
    Cantor Fitzgerald
    10/4/2024$17.00Overweight
    Wells Fargo
    More analyst ratings

    $ATYR
    SEC Filings

    View All

    SEC Form 10-Q filed by aTyr Pharma Inc.

    10-Q - aTYR PHARMA INC (0001339970) (Filer)

    11/6/25 4:17:24 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - aTYR PHARMA INC (0001339970) (Filer)

    11/6/25 4:08:11 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by aTyr Pharma Inc.

    SCHEDULE 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    10/7/25 11:03:42 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schimmel Paul bought $911,801 worth of shares (1,000,000 units at $0.91) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    10/9/25 6:30:21 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Zaknoen Sara

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    5/2/25 5:25:06 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Schimmel Paul

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    5/2/25 5:23:44 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

    Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Company plans to meet with the FDA to determine path forward for efzofitimod in pulmonary sarcoidosis in the first quarter of 2026.  Company expects to complete enrollment in Phase 2 EFZO-CONNECT™ study of efzofitimod in systemic sclerosis-related interstitial lung disease (SSc-ILD) in the first half of 2026. Ended the third quarter 2025 with $92.9 million in cash, cash equivalents, restricted cash and investments. SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of fi

    11/6/25 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

    Clinical benefit for efzofitimod across multiple disease-related health outcomes reported. Improvement in Fatigue Assessment Scale Total Score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0226). Improvement in King's Sarcoidosis Questionnaire-General Health score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0197). SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today presented additional findings from the P

    9/30/25 5:30:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

    Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King's Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of patients achieved complete steroid withdrawal at week 48 with a KSQ-Lung score improvement in the 5.0 mg/kg efzofitimod treatment group (29.5%) vs placebo (14.4%) (p=0.0199

    9/15/25 7:30:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Leadership Updates

    Live Leadership Updates

    View All

    aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

    SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise. Ms. Rayes brings over 25 years of experience building and leading commercial organizations at biotechnology and pharmaceutical companies, including leading rare disease product launches. She will serve as a member of the Company's executive leadership team, overseeing global commercial strategy and operations for the efzofitimod prog

    3/26/25 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

    SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Eric Benevich to the Company's Board of Directors, effective as of December 10, 2024. Mr. Benevich currently serves as Chief Commercial Officer at Neurocrine Biosciences, Inc. (Neurocrine). "We are excited to welcome Eric Benevich to the Board of Directors," said Timothy P. Coughlin, Chairman of the Board of aTyr. "His extensive background bringing new products to market and the knowledge and experti

    12/12/24 4:00:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

    SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company's executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product lif

    8/6/24 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Financials

    Live finance-specific insights

    View All

    aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

    Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King's Sarcoidosis Questionnaire (KSQ)-Lung score at week 48 observed in the 5.0 mg/kg efzofitimod treatment group vs placebo (p=0.0479). Greater proportion of patients achieved complete steroid withdrawal at week 48 with a KSQ-Lung score improvement in the 5.0 mg/kg efzofitimod treatment group (29.5%) vs placebo (14.4%) (p=0.0199

    9/15/25 7:30:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

    Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforces its favorable safety profile. Publication in Science Translational Medicine validates efzofitimod's mechanism of action. Company to host conference call and webcast today, March 13th at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, March 13, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announc

    3/13/25 4:01:00 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

    SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it will report fourth quarter and full year 2024 financial results and provide a corporate update after the market close on Thursday, March 13, 2025. Management will host a conference call and webcast to review the results and provide an operational update. Conference Call and Webcast Details:Date: Thursday, March 13, 2025Time: 5:00 p.m. EDT / 2:00 p.m. PDTDial-In Registration: https://register.vevent.com/register/BI00725a32705e4ee3b22d05

    3/4/25 8:00:00 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schimmel Paul bought $911,801 worth of shares (1,000,000 units at $0.91) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    10/9/25 6:30:21 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gross Jane A bought $15,000 worth of shares (3,750 units at $4.00), increasing direct ownership by 62% to 9,750 units (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    3/17/25 7:07:42 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Schimmel Paul bought $184,613 worth of shares (100,000 units at $1.85) (SEC Form 4)

    4 - aTYR PHARMA INC (0001339970) (Issuer)

    7/24/24 5:29:51 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    aTyr Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded aTyr Pharma from Outperform to Sector Perform and set a new price target of $1.50

    9/16/25 8:00:57 AM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded aTyr Pharma from Overweight to Equal Weight and set a new price target of $1.00

    9/15/25 1:24:32 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    aTyr Pharma downgraded by H.C. Wainwright

    H.C. Wainwright downgraded aTyr Pharma from Buy to Neutral

    9/15/25 12:10:02 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ATYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    11/14/24 6:51:17 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by aTyr Pharma Inc.

    SC 13G - aTYR PHARMA INC (0001339970) (Subject)

    10/15/24 5:01:55 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by aTyr Pharma Inc.

    SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)

    10/7/24 1:36:35 PM ET
    $ATYR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care